Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Phillip A. Hsieh"'
3
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
Autor: Shih-Feng Cho, Yu-Tzu Tai, Tengteng Yu, Lijie Xing, C. Andrew Stewart, Metin Kurtoglu, Yi Zhang, Kenneth C. Anderson, Hailin Chen, Yuyin Li, Liang Lin, Kenneth Wen, Phillip A Hsieh, Nikhil C. Munshi
Publikováno v: Leukemia
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, D
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::825fbbb74663e8f6266b7613e54b6227
http://europepmc.org/articles/PMC7785573
Zobrazit plný text záznamu
4
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Autor: Lijie Xing, Liang Lin, Kenneth Wen, Phillip A Hsieh, Hailin Chen, Gang An, Krista Kinneer, Su Wang, Yuyin Li, Jiye Liu, Kenneth C. Anderson, Lugui Qiu, Shih-Feng Cho, Nikhil C. Munshi, Yu-Tzu Tai, Tengteng Yu
Publikováno v: Clin Cancer Res
Purpose: Efforts are required to improve the potency and durability of CD38- and BCMA-based immunotherapies in human multiple myeloma. We here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by BCM
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8fafac004bb2d65d171a7efd1f3a651
https://pubmed.ncbi.nlm.nih.gov/34301753
Zobrazit plný text záznamu
5
OAB-021: BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via enhanced IFN-driven innate immune responses and expression of CD38 and NKG2D ligands
Autor: Shih-Feng Cho, Yu-Tzu Tai, Tengteng Yu, Jiye Liu, Nikhil C. Munshi, Hailin Chen, Kenneth Wen, Lijie Xing, Lugui Qiu, Su Wang, Kenneth C. Anderson, Gang An, Phillip A Hsieh
Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S13-S14
Background Efforts are required to improve potency and durability of CD38- and BCMA-based immunotherapies in human multiple myeloma (MM). Methods We here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects trigg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd239258f9d732ff0dcfc40ce72d892d
https://doi.org/10.1016/s2152-2650(21)02095-4
Zobrazit plný text záznamu
6
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
Autor: Liang Lin, Tara Arvedson, Matthias Friedrich, Shih-Feng Cho, Kenneth Wen, Yu-Tzu Tai, Tengteng Yu, Yuyin Li, Kenneth C. Anderson, Nikhil C. Munshi, Katja Matthes, Joachim Wahl, Lijie Xing, Phillip A Hsieh
Publikováno v: Blood Adv
We investigated here the novel immunomodulation and anti–multiple myeloma (MM) function of T cells engaged by the bispecific T-cell engager molecule AMG 701, and further examined the impact of AMG 701 in combination with immunomodulatory drugs (IMi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1394b3c8ed83bc5631a8855108c0d22e
https://europepmc.org/articles/PMC7479960/
Zobrazit plný text záznamu
7
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Autor: Yan Xu, Phillip A Hsieh, Gang An, Hedy Adari, Kenneth C. Anderson, Yuyin Li, Zachary Shriver, Kenneth Wen, Lijie Xing, Lugui Qiu, Gregory J. Babcock, James R. Myette, Liang Lin, Andrew M. Wollacott, Bharat Chaganty, Boopathy Ramakrishnan, Hailin Chen, Wenjuan Yang, Karthik Viswanathan, Nikhil C. Munshi, Shih-Feng Cho, Yu-Tzu Tai, Tengteng Yu
Publikováno v: Blood Cancer Journal
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-13 (2020)
Therapeutically targeting CD138, a define multiple myeloma (MM) antigen, is not yet approved for patients. We here developed and determined the preclinical efficacy of VIS832, a novel therapeutic monoclonal antibody (MoAb) with differentiated CD138 t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5b9b17431444737382fe397df9de1c3
https://pubmed.ncbi.nlm.nih.gov/33149123
Zobrazit plný text záznamu
8
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
Autor: Andrea van Elsas, John Dulos, Chirag Acharya, Phillip A Hsieh, Paul G. Richardson, Nikhil C. Munshi, Yu-Tzu Tai, Tengteng Yu, Shih-Feng Cho, Kenneth Wen, Lijie Xing, Kenneth C. Anderson, Liang Lin
Publikováno v: Leukemia
We investigate here how APRIL impacts immune regulatory T cells and directly contributes to the immunosuppressive multiple myeloma (MM) bone marrow (BM) microenvironment. First, APRIL receptor TACI expression is significantly higher in regulatory T c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a782f29c83f68d06fb79b500a67c7e36
https://doi.org/10.1038/s41375-018-0242-6
Zobrazit plný text záznamu
10
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
Autor: Yu-Tzu Tai, Tengteng Yu, Liang Lin, Nikhil C. Munshi, Jiye Liu, Krista Kinneer, Lijie Xing, Kenneth C. Anderson, Yuyin Li, Phillip A Hsieh, Kenneth Wen, Shih-Feng Cho
Publikováno v: Leukemia
To target mechanisms critical for multiple myeloma (MM) plasma cell adaptations to genomic instabilities and further sustain MM cell killing, we here specifically trigger DNA damage response (DDR) in MM cells by a novel BCMA antibody-drug conjugate (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0d8cbccb4efbe35dcab5c5243c8d60
https://pubmed.ncbi.nlm.nih.gov/32060401
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje